Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Study to examine if new eczema drug may prevent future development of asthma

19.11.2003


Children’s Memorial Hospital is the only Chicago site for a study to determine whether early treatment of eczema using one of a new class of anti-inflammatory drugs will prevent subsequent development of asthma and other allergic diseases. Prevalence of eczema, or atopic dermatitis, has tripled in the last few decades, in parallel with asthma. Investigators at Children’s Memorial are part of a national clinical trial involving 1,100 children, from 3 to 18 months old, to test pimecrolimus (Elidel), one of a new class of drugs called calcineurin inhibitors. Used in a cream form, pimecrolimus prevents the production of chemicals in the immune system that cause eczema symptoms, including redness, itching, cracking and bleeding.



The six-year prospective study, funded by Novartis, will be conducted in two stages. During the first three years a double blind study will compare the safety and effectiveness of pimecrolimus in conjunction with corticosteroid therapy for flare-ups, vs. corticosteroid therapy alone. Investigators hope that early treatment with pimecrolimus will reduce or prevent the need for corticosteroids. In the second three years, patients will be followed to see if they develop other allergic diseases, such as asthma, allergic rhinitis (hay fever), or allergic conjunctivitis (eye redness).

"The hope is that early and effective topical treatment of eczema in its early stages may help to prevent the later development of asthma, allergic rhinitis or allergic conjunctivitis," says Amy Paller, MD, lead site investigator and researcher at Children’s Memorial Institute for Education and Research. Paller, head of dermatology at Children’s Memorial, is professor of pediatrics and dermatology at Northwestern University’s Feinberg School of Medicine.


"While eczema develops from birth to about three years of age in most affected children, other allergies such as asthma, begin in early childhood, and hay fever begins even later," she says. "We know that 50 to 80 percent of children who have eczema in infancy or childhood go on to develop asthma or other allergic diseases later on, especially if others in their immediate family have allergic disease. But we don’t now why."

According to Paller, recent studies in mice have shown that when an allergenic substance, egg protein, was applied onto broken skin, the animals subsequently showed an allergic, asthma-like response in the lungs when exposed to the egg protein through lung inhalation. The lungs of mice whose skin had been exposed to salt water did not show an allergic response to the egg protein. This may indicate that allergenic substances that enter the bloodstream through untreated or poorly managed eczema can trigger later allergic responses, including asthma, hay fever and other conditions.

To be considered for the study, babies must have been diagnosed with eczema within the past three months, and have a parent or sibling with eczema, asthma, allergic rhinitis or allergic conjunctivitis.

Pimecrolimus has been tested for safety and effectiveness in hundreds of babies, and it is currently approved for use in eczema by the U.S. Food and Drug Administration for children as young as 2 years of age.

Children’s Memorial Institute for Education and Research is the research arm of Children’s Memorial Hospital and the center for pediatric research at Northwestern University. Children’s Memorial Hospital is the pediatric teaching hospital for Northwestern University’s Feinberg School of Medicine.

Ellen M. Hunt | EurekAlert!
Further information:
http://www.childrensmemorial.org/

More articles from Health and Medicine:

nachricht 'Icebreaker' protein opens genome for t cell development, Penn researchers find
21.02.2018 | University of Pennsylvania School of Medicine

nachricht Similarities found in cancer initiation in kidney, liver, stomach, pancreas
21.02.2018 | Washington University School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: In best circles: First integrated circuit from self-assembled polymer

For the first time, a team of researchers at the Max-Planck Institute (MPI) for Polymer Research in Mainz, Germany, has succeeded in making an integrated circuit (IC) from just a monolayer of a semiconducting polymer via a bottom-up, self-assembly approach.

In the self-assembly process, the semiconducting polymer arranges itself into an ordered monolayer in a transistor. The transistors are binary switches used...

Im Focus: Demonstration of a single molecule piezoelectric effect

Breakthrough provides a new concept of the design of molecular motors, sensors and electricity generators at nanoscale

Researchers from the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague), Institute of Physics of the CAS (IP CAS) and Palacký University...

Im Focus: Hybrid optics bring color imaging using ultrathin metalenses into focus

For photographers and scientists, lenses are lifesavers. They reflect and refract light, making possible the imaging systems that drive discovery through the microscope and preserve history through cameras.

But today's glass-based lenses are bulky and resist miniaturization. Next-generation technologies, such as ultrathin cameras or tiny microscopes, require...

Im Focus: Stem cell divisions in the adult brain seen for the first time

Scientists from the University of Zurich have succeeded for the first time in tracking individual stem cells and their neuronal progeny over months within the intact adult brain. This study sheds light on how new neurons are produced throughout life.

The generation of new nerve cells was once thought to taper off at the end of embryonic development. However, recent research has shown that the adult brain...

Im Focus: Interference as a new method for cooling quantum devices

Theoretical physicists propose to use negative interference to control heat flow in quantum devices. Study published in Physical Review Letters

Quantum computer parts are sensitive and need to be cooled to very low temperatures. Their tiny size makes them particularly susceptible to a temperature...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

2nd International Conference on High Temperature Shape Memory Alloys (HTSMAs)

15.02.2018 | Event News

Aachen DC Grid Summit 2018

13.02.2018 | Event News

How Global Climate Policy Can Learn from the Energy Transition

12.02.2018 | Event News

 
Latest News

Researchers invent tiny, light-powered wires to modulate brain's electrical signals

21.02.2018 | Life Sciences

The “Holy Grail” of peptide chemistry: Making peptide active agents available orally

21.02.2018 | Life Sciences

Atomic structure of ultrasound material not what anyone expected

21.02.2018 | Materials Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>